← Back to Analyst Consensus 
FENC Buy
FENNEC PHARMACEUTICALS INC.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 12, 2026 | B. Riley Securities | reiterate | Buy → Buy | — | 55% |
| Aug 12, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 16, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jan 9, 2026 | Piper Sandler | initiate | — → Overweight | $18 | 54% |
| Aug 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Aug 15, 2025 | Craig-Hallum | maintain | Buy → Buy | $14 | 54% |
| May 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| May 14, 2025 | Craig-Hallum | maintain | Buy → Buy | $13 | 54% |
| Mar 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Dec 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Aug 22, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Aug 14, 2024 | Craig-Hallum | maintain | Buy → Buy | $15 | 54% |
| May 15, 2024 | Craig-Hallum | maintain | Buy → Buy | $17 | 54% |
| May 15, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| Apr 4, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Mar 18, 2024 | Craig-Hallum | maintain | Buy → Buy | $18 | 54% |
| Aug 4, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $17 | 44% |
| Jun 21, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Apr 6, 2023 | Cantor Fitzgerald | maintain | — → Overweight | $16 | 50% |
| Apr 4, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $18 | 44% |
| Mar 31, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $18 | 44% |
| Jan 26, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $18 | 44% |
| Nov 22, 2022 | Cantor Fitzgerald | upgrade | Neutral → Overweight | $12 | 50% |
| Oct 20, 2022 | HC Wainwright & Co. | maintain | — → Buy | $18 | 44% |
| Sep 26, 2022 | Wedbush | maintain | — → Outperform | $19 | 58% |
| Sep 7, 2022 | Capital One | initiate | — → Overweight | $11 | 30% |
| Jun 3, 2021 | HC Wainwright & Co. | maintain | — → Buy | $14 | 44% |
| Apr 21, 2021 | Craig-Hallum | initiate | — → Buy | $17 | 54% |
| Apr 19, 2021 | Maxim Group | initiate | — → Buy | $12 | 42% |
| Jun 5, 2020 | Cantor Fitzgerald | initiate | — → Overweight | $18 | 50% |
| May 15, 2020 | HC Wainwright & Co. | reiterate | — → Buy | $15 | 44% |
| Sep 17, 2018 | Wedbush | maintain | Outperform → Outperform | $16 | 58% |
| Mar 12, 2018 | Wedbush | initiate | — → Outperform | $17 | 58% |
| Feb 20, 2018 | HC Wainwright & Co. | initiate | — → Buy | $16 | 44% |
Price Target Trend
Apr 22, 2026 Latest: $17.67 Oct 24, 2026
EPS Estimates
+1q $0.14
Lo: $0.09 Hi: $0.22
5 analysts +1y $0.95
Lo: $0.63 Hi: $1.42
5 analysts 0q $0.11
Lo: $0.06 Hi: $0.16
5 analysts 0y $0.32
Lo: $0.20 Hi: $0.52
5 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days